文献速递心力衰竭与心肌病心律失常

DSG2/DSC2变异相关致心律失常性右室心肌病的自然史与临床结局

Natural History and Clinical Outcomes of Patients With DSG2/DSC2 Variant-Related Arrhythmogenic Right Ventricular Cardiomyopathy.
PubMed 文献 · Circulation · 2025-03-24

该研究收集欧洲和亚洲5个国家的DSG2/DSC2变异携带者数据,描述其表型表达、自然史和临床结局。共纳入271例受试者,其中254例携带DSG2变异,中位年龄38岁,62.7%为男性。多变异携带者更易诊断为ARVC、发病更早且左室功能不全更严重,随访中终末期心衰和恶性室性心律失常更频繁。

要点

  • 多变异携带者ARVC诊断率更高(96.2% vs 64.8%),发病年龄更早。
  • 多变异携带者左室功能不全和右室扩张更严重,随访中心衰和恶性室性心律失常更频繁。
  • DSG2/DSC2患者终末期心衰风险显著高于PKP2患者。

核心结论

  • DSG2/DSC2变异相关ARVC多表现为右室或双室病变,多变异常见且与更高临床外显率、更早发病和不良结局相关。

研究设计与样本

  • 研究收集来自欧洲和亚洲5个国家的DSG2和DSC2变异携带者的遗传和临床数据。
  • 共纳入271例受试者,其中254例携带DSG2变异,165例为先证者,200例诊断为明确ARVC。

主要发现

  • 181例(66.8%)携带错义变异,主要分布于细胞外结构域,78例(28.8%)携带多变异。
  • 200例明确ARVC患者中,41例(20.5%)在65岁前发生早发心脏性死亡。
  • 81例有左室射血分数和右室面积变化分数数据的患者中,29例(35.8%)为孤立性右室功能不全,16例(19.8%)为双室功能不全。
  • 与单变异携带者相比,多变异携带者ARVC诊断率更高(96.2% vs 64.8%,P<0.001),左室功能不全更严重(44.4% vs 22.1%,P=0.001),右室扩张更常见(88.9% vs 55.8%,P<0.001)。
  • 多变异携带者ARVC诊断年龄更年轻(33 [18-49]岁 vs 42 [27-54]岁,P<0.001),随访中终末期心衰(P<0.001)和恶性室性心律失常(P=0.004)更频繁。

关键数值与推荐

  • 单变异携带者中,进行高强度体育锻炼者疾病发病年龄更年轻(P=0.001)。
  • 与PKP2患者相比,DSG2/DSC2患者终末期心衰风险显著更高(P<0.001)。

临床怎么用

  • 对DSG2/DSC2变异携带者应评估多变异状态,多变异提示更高风险和更早发病。
  • 携带多变异者需更密切监测心衰和恶性室性心律失常,并考虑更早干预。
  • 高强度体育锻炼与单变异携带者更早发病相关,应纳入生活方式管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic variants in desmosomal cadherins, desmoglein 2 (DSG2) and desmocollin 2 (DSC2), cause a distinct form of arrhythmogenic right ventricular cardiomyopathy (ARVC), which remains poorly reported. In this study, we aimed to provide a comprehensive description of the phenotypic expression, natural history, and clinical outcomes of patients with this ARVC subset. METHODS: Genetic and clinical data of DSG2 and DSC2 variant carriers were collected from 5 countries in Europe and Asia. We assessed the phenotypic profile of these patients and their clinical outcomes, focusing on heart failure and ventricular arrhythmia events. RESULTS: Overall, 271 subjects, 254 with DSG2 variants, were included in this study (median age, 38 years [interquartile range, 25-52]; 62.7% male). Of these, 165 were probands, and 200 were diagnosed with definite ARVC. A total of 181 (66.8%) individuals carried missense variants, mainly distributed in the extracellular domains. Notably, we included 78 (28.8%) individuals with multiple variants. Of the 200 cases with diagnosed ARVC, 41 (20.5%) experienced premature cardiac death before the age of 65. Among the 81 individuals for whom both left ventricular ejection fraction and right ventricular fractional area change data were available at presentation, 29 (35.8%) had isolated right ventricular dysfunction, and 16 (19.8%) had biventricular dysfunction. Single-variant carriers who engaged in intense physical exercise were younger at disease onset compared with those who did not (P=0.001). Compared with single-variant carriers, those with multiple variants were more likely to be diagnosed with ARVC (96.2% versus 64.8%; P<0.001) and exhibited more severe left ventricular dysfunction (44.4% versus 22.1%; P=0.001) and right ventricular dilation (88.9% versus 55.8%, P<0.001). Multiple-variant carriers were significantly younger at ARVC diagnosis compared with single-variant carriers (33 [18-49] years versus 42 [27-54] years; P<0.001]. During follow-up, end-stage heart failure (P<0.001) and malignant ventricular arrhythmias (P=0.004) were significantly more frequent in multiple-variant compared with single-variant carriers. Compared with PKP2 patients, DSG2/DSC2 patients exhibited a significantly higher risk of end-stage heart failure (P<0.001). CONCLUSIONS: ARVC attributable to variants in desmosomal cadherins mostly present with right ventricular or biventricular disease. Multiple variants are common in these patients and are associated with more frequent clinical penetrance, earlier onset of disease, and adverse clinical outcomes.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Chen L, Hu Y, Saguner AM, et al. Natural History and Clinical Outcomes of Patients With DSG2/DSC2 Variant-Related Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2025. PMID: 40123482. doi:10.1161/CIRCULATIONAHA.124.072226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。